Montelex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Montelex

What is Montelex?

Montelex is a therapeutic medication belonging to a class of drugs known as leukotriene receptor antagonists. It is primarily utilized in the management and long-term treatment of respiratory conditions characterized by airway inflammation and constriction.

Mechanism of Action

The active component in Montelex works by blocking the action of leukotrienes. Leukotrienes are naturally occurring chemicals in the body that are released during an inflammatory response, such as when an individual encounters an allergen or irritant. In the respiratory system, these chemicals cause the muscles around the airways to tighten and lead to swelling and mucus production in the lungs. By binding to specific receptors and inhibiting these chemicals, Montelex helps to keep the bronchial tubes open and reduces the inflammatory processes in the respiratory tract.

Primary Uses

Montelex is commonly used for the following purposes:

  • Asthma Management: It is used as a maintenance treatment to prevent the frequency and severity of asthma symptoms in both adults and children. It helps improve daily lung function and reduces the necessity for rescue inhalers.
  • Allergic Rhinitis: The medication is also used to relieve symptoms associated with seasonal or perennial allergies, such as sneezing, nasal congestion, and a runny or itchy nose.
  • Exercise-Induced Bronchoconstriction: It may be used to prevent the narrowing of airways that occurs specifically during or after physical exertion.

Characterization

Unlike rescue medications that provide immediate relief during an acute asthma attack, Montelex is a controller medication. It is designed to be used consistently to provide ongoing protection and stabilization of the airways. It is not intended for the treatment of sudden shortness of breath and does not replace fast-acting bronchodilators.

Regulatory References

  1. Montelukast - StatPearls - NCBI Bookshelf - NIH
  2. Leukotriene Receptor Antagonists - StatPearls - NCBI Bookshelf - NIH
  3. National Institutes of Health (NIH), StatPearls on Montelukast
  4. MedlinePlus Montelukast Drug Information

What side effects are possible with Montelex?

Possible Side Effects and Safety Information

The safety profile of Montelex (montelukast sodium) is officially described using standardized regulatory classifications that detail observed adverse reactions by frequency and affected body system. The frequency framework categorizes effects from very common to very rare.

Frequency-Classified Adverse Reactions

The most frequently documented events, classified as Very Common or Common in regulatory documents, include upper respiratory infection, headache, fever, and gastrointestinal symptoms like abdominal pain, diarrhea, and nausea. Less common effects, such as hypersensitivity reactions, dream abnormalities, and dizziness, are also officially listed.

Specific Safety Concerns and Systemic Effects

Adverse reactions are grouped into System-Organ Classes (SOC), spanning areas such as Infections, Gastrointestinal Disorders, Nervous System Disorders, and Psychiatric Disorders. Serious adverse reactions are specifically highlighted in regulatory labeling:

  • Neuropsychiatric Events: The official prescribing information documents a range of neuropsychiatric events, including agitation, depression, aggressive behavior, and in rare cases, suicidal thoughts and behavior. These have been reported during treatment and sometimes after discontinuation.
  • Systemic Conditions: Rare post-marketing reports include systemic eosinophilia, sometimes presenting as features consistent with Churg-Strauss syndrome, and forms of hepatitis (liver injury).

Population and Regulatory Constraints

The official labeling includes safety notes specific to patient groups, such as observations on the safety profile for pediatric patients and those with hepatic impairment. Montelex is strictly contraindicated in individuals with known hypersensitivity to the active substance or its components. Patients with known aspirin sensitivity should officially continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking the medicine.

Overdose and Emergency Response

Official Documentation of Overdose

Montelex (montelukast sodium) overdose information is based on reports detailed in official government prescribing documents. These regulatory sources confirm the manifestations most frequently reported in cases of acute overdose.

The documented clinical manifestations include abdominal pain, somnolence (drowsiness), headache, thirst, vomiting, and psychomotor hyperactivity. Regulatory analysis indicates that clinical and laboratory findings in the majority of overdose reports, which included acute doses up to 1,000 mg, were generally consistent with the established adverse reaction profile of the medication across both adult and pediatric patients.

When to Seek Immediate Help

Seek immediate medical attention for any suspected overdose or if any of the documented manifestations are observed. It is mandated to contact a Poison Control Center or emergency services in such situations, as directed by official regulatory guidance.

Management and Supportive Care

Regulatory documents state that there is no specific antidote known for Montelex overdose. Therefore, the management of overdose is restricted to symptomatic and supportive treatment, as clinically indicated by the patient’s presentation.

Furthermore, official labeling notes that it is not known whether the substance can be effectively removed from the body via hemodialysis or peritoneal dialysis.

Therapeutic Uses of Montelex

Montelex may assist in managing symptoms associated with certain chronic respiratory and allergic conditions. It is typically used as a maintenance treatment to help alleviate the effects of asthma, including both day-time and night-time symptoms, as well as those triggered by exercise. The medication also helps address the symptoms of persistent allergic rhinitis (seasonal and perennial hay fever), such as sneezing and a runny nose. Additionally, Montelex may be employed to reduce the discomfort and itching related to chronic urticaria (hives) in some patients. Integrating this medication into a treatment plan may support improved breathing and enhanced patient well-being when dealing with these indications.


Quick Fact: Therapeutic Support

Montelex may help manage the symptoms of chronic asthma, allergic rhinitis, and chronic hives.

Eligibility and Restrictions for Use

The eligibility for using Montelex (montelukast sodium) is strictly defined by regulatory authorities based on absolute prohibitions, age, and existing physiological conditions.

Absolute Contraindications

Montelex is contraindicated in patients with known hypersensitivity to the active substance or any component. It must not be used for reversing bronchospasm in an acute asthma attack or status asthmaticus, as it is strictly a long-term controller medicine. The chewable tablet formulation should also not be used by patients with Phenylketonuria (PKU) due to the presence of phenylalanine.


Age and Condition Restrictions

Age Group Restriction Condition Use Status
<12 months Asthma Use not established
<2 years Seasonal Allergic Rhinitis Use not established
Geriatric / Renal Impairment Chronic Use No adjustment required

Conditional Use and Limitations

The label restricts use in several specific populations. Patients with severe hepatic impairment have not been evaluated, meaning use is not established. During pregnancy and lactation, use is conditional, permitted only if considered clearly essential. For allergic rhinitis, Montelex is reserved for patients who have an inadequate response to alternative therapies.

What should I know about interactions with other medicines?

Montelex’s official regulatory interaction profile is defined primarily by pharmacokinetic (PK) interactions, which alter its concentration in the body. The drug is metabolized by CYP enzymes, and co-administration with enzyme-altering substances is officially documented to change its systemic exposure.

Official Exposure-Altering Interactions

Substance Interaction Type Formal Outcome
Phenobarbital CYP Induction Decreases systemic exposure (AUC) by approx 40%
Gemfibrozil CYP Inhibition Increases systemic exposure (AUC) by 4.4-fold

Pharmacodynamic and Restriction Rules

Specific restrictions are officially documented: Co-administration is prohibited with any other medicinal products containing montelukast. Furthermore, for patients with known aspirin-sensitive asthma, Montelex does not negate the necessity to continue the avoidance of aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Non-Significant Interactions

Other interactions are classified as non-significant. Montelex is documented to have no clinically important effects on the pharmacokinetics of co-administered agents such as Theophylline, Digoxin, or Warfarin. The drug may be taken with or without food, as its systemic exposure is not significantly affected by meals.

Population-Specific Notes

A note of caution is cited for patients with impaired hepatic function, as the drug is primarily cleared via the bile. Caution is also noted for the co-administration of the potent inducer Rifampicin in pediatric populations.

Mechanism of Action

How Montelex Works

Montelex exerts its pharmacologic effects through highly specific interactions within targeted biological signaling pathways. Its primary mechanism centers on modulating receptor- or enzyme-mediated signaling to influence activity within specific biological systems.

Modulation of Key Receptor Signaling

Montelex engages mechanisms that act within domains involving receptor-mediated signaling, specifically by initiating or suppressing signaling sequences that lead to downstream effects. This process affects systems where specific transmitters or mediators dominate, thereby influencing physiological responses associated with excessive mediator activity by reducing the concentration or duration of activity of targeted mediators.


Regulating Signal Transduction Patterns

The compound modifies early molecular steps and modulates key signaling pathways that influence systemic physiological outcomes. It alters pathway activity associated with specific signal transduction patterns, particularly in contexts involving rapid modulation of physiological responses. This engagement with the mechanistic cascades influences feedback regulation mechanisms within targeted pathways, resulting in changes in downstream physiological parameters.

Dosage and Administration Information

Administration Guidelines for Montelex

Montelex (montelukast sodium) is an oral medication intended for once-daily administration, as prescribed by healthcare providers for long-term maintenance. Administration is typically defined by the dose, timing, and preparation steps based on age and the indication being treated.


Standard Dosing and Timing

Patient Group Dose & Form Standard Timing Maximum Dose
Adults/Adolescents (ge 15 years) 10 mg tablet Once daily, in the evening (for asthma or asthma + rhinitis) 10 mg/24 hours
Children (6-14 years) 5 mg chewable tablet Once daily, in the evening (for asthma) 5 mg/24 hours
Children (2-5 years) 4 mg chewable tablet or granules Once daily, in the evening (for asthma) 4 mg/24 hours

For allergic rhinitis alone, the dose may be individualized to be taken in the morning or evening. When treating both asthma and allergic rhinitis, patients must only take a single dose daily in the evening.


Administration Instructions

  • Food Relation: Film-coated tablets can be taken with or without food. Chewable tablets and granules are generally taken without regard to the time of food ingestion.
  • Oral Granules Preparation: The 4 mg granules can be administered directly into the mouth or mixed with a spoonful of cold or room-temperature soft foods (e.g., applesauce, rice, carrots) or 5 mL of baby formula/breast milk. The entire dose must be administered within 15 minutes of opening the packet or mixing. Unused portions must be discarded.
  • Missed Dose: If a dose is missed, patients should take the next scheduled dose at the regular time. Do not take two doses to compensate for the missed one.
  • EIB Prophylaxis: When used for prevention of exercise-induced bronchoconstriction, a single 10 mg dose should be taken at least 2 hours before exercise. An additional dose must not be taken within 24 hours of a previous dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Montelex

Evidence for Use in Chronic Asthma

Research for chronic asthma was studied in various randomized, placebo-controlled trials, comparative studies, and observational reports. Researchers examined outcomes related to functional balance, such as the Forced Expiratory Volume in 1 second (FEV1), and daily functioning, like night-time awakenings. Initial short-term trials reported measurements of FEV1 and symptom scores where observed differences existed compared to placebo. Comparative studies examining outcomes against inhaled corticosteroids (ICS) reported different magnitudes of measured change between the two groups. Research also described patterns related to outcomes in subgroups that included those with exercise-induced symptoms.


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research on allergic rhinitis included short-term randomized trials that monitored symptoms of this condition, which is characterized by fluctuating or episodic manifestations. Studies examined patients from children (aged 6 months) to adults, evaluating physical discomfort using symptom scales like the Total Nasal Symptom Score (TNSS). Findings from short-term trials reported measurements that showed a change in nasal symptom scores compared to placebo. Studies evaluating oral antihistamines described a similar magnitude of measured change in symptoms, while outcomes in comparative studies sometimes described a smaller magnitude than intranasal corticosteroids.


Long-Term Evidence and Maintenance Data

Most core efficacy research focused on short-term responses, typically over 4 to 12 weeks. Long-term studies and observational reports have been applied in studies examining patient-reported experiences over longer intervals. However, high-quality, long-term, randomized trial data detailing the durability of the initial measured changes remains less comprehensive. Long-term effects are not fully established when compared directly against alternative treatments in that context.


Evidence in Special Populations

Research explored use in several patient groups, including children as young as 1 year for asthma and 6 months for perennial allergic rhinitis. For patients aged 50 and older, pilot studies were conducted, but findings were mixed, with some studies reporting that the measured differences in asthma control scores and lung function compared to the placebo group were limited in that specific age group. Limited information is available for very young children (under 6 months).


What Remains Uncertain About Montelex Research

Regulatory agencies have advised that the use of Montelex for allergic rhinitis be reserved for patients whose symptoms are not adequately addressed by or who cannot tolerate alternative treatments. Regulatory reviews noted that observational data have limitations regarding long-term associations.

Key Studies & References

  1. Montelukast - StatPearls - NCBI Bookshelf
  2. Montelukast Sodium Tablet, Film Coated - U.S. FDA Labeling/DailyMed
  3. Montelukast: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Montelex (FAQ)

Q: What is the main reason doctors prescribe Montelex?

According to official labeling, Montelex is prescribed for three main purposes: the long-term, ongoing maintenance treatment of persistent asthma, the prevention of breathing difficulty related to exercise, and the relief of symptoms caused by seasonal or perennial allergic rhinitis.

Q: Is Montelex considered a common drug for this condition?

Montelukast, the active ingredient in Montelex, is used globally for its approved indications. However, for the treatment of allergic rhinitis, regulatory agencies have advised that its use be reserved for those whose symptoms are not adequately addressed by or who cannot tolerate alternative treatments.

Q: How does Montelex compare generally to other medicines for this condition?

Official regulatory sources classify Montelex as a leukotriene receptor antagonist (LTRA). Regulatory reviews describe its positioning relative to inhaled corticosteroids for long-term asthma control. For allergic rhinitis, official guidance suggests reserving its use for patients who do not respond adequately to or cannot tolerate other available treatments.

Q: How quickly should I expect to see an effect from Montelex?

The active substance in Montelex is rapidly absorbed after the first dose. However, because this is a controller medicine designed for maintenance, it may take about one day to begin improving symptoms of asthma. The full magnitude of measured effects from the medicine is often noted after several weeks of continuous daily use.

Q: Does Montelex start working right away?

Yes, the active ingredient in Montelex is rapidly absorbed into the bloodstream. This medicine is intended for long-term control of chronic symptoms, rather than for immediate relief of an acute attack. Consistent daily use is required for optimal, ongoing effectiveness.

Q: Is it normal to feel a bit dizzy when first starting Montelex?

Official product information states that dizziness has been reported as an uncommon side effect of this medicine, potentially affecting up to 1 in 100 people. If a person experiences dizziness or other changes related to the nervous system, regulatory guidance indicates these symptoms should be discussed with a healthcare provider.

Q: Will Montelex affect my ability to drive or operate machinery?

Regulatory product information notes that certain side effects, including dizziness and somnolence (drowsiness or sleepiness), may occur with Montelex. These effects could potentially impair the ability to drive or operate complex machinery. Official documentation states that patients should be aware of how the medicine affects them before performing such activities.

Q: Can I drink alcohol while I am on Montelex?

Official regulatory labeling does not contain a specific direct warning about an interaction between Montelex and alcohol. However, Montelex has been associated with rare post-marketing reports of liver injury. If there are concerns, official guidance suggests patients discuss alcohol use with their healthcare provider.

Q: Does Montelex interact with birth control pills?

Studies documented in the official prescribing information indicate that Montelex did not show a clinically important effect on the way the body handles common oral contraceptives. This included combinations of norethindrone and ethinyl estradiol.

Q: I take a supplement; could it interact with Montelex?

Interactions between Montelex and many common herbal remedies or nutritional supplements have not been tested or documented to the same extent as those with prescription medicines. Official guidance emphasizes the importance of informing the healthcare team, including the pharmacist, about all supplements and vitamins currently being used.

Q: Is Montelex safe to take with blood pressure medication?

The official drug information does not list any specific contraindications involving common blood pressure medications. Montelex was used concurrently with a variety of other widely prescribed medicines during clinical studies without reports of clinically significant adverse interactions.

Q: What should I do if I suspect an allergic reaction to Montelex?

Serious allergic reactions, including anaphylaxis, are possible with any medication. Official patient information indicates that if signs such as sudden swelling of the face, tongue, or throat, or difficulty breathing occur, immediate emergency medical attention may be needed.

Q: Is Montelex an FDA-approved medication?

Yes, the active ingredient in Montelex, montelukast sodium, has received approval from the U.S. Food and Drug Administration (FDA). It has also been approved by other major governmental regulatory bodies worldwide for the treatment of its labeled indications.

Q: Have there been any major recent updates to the safety information for Montelex?

Yes, regulatory agencies have recently reinforced and highlighted safety warnings concerning the risk of neuropsychiatric events. These are serious side effects that include behavioral changes, mood disturbances, depression, and, in rare instances, suicidal thoughts or behavior.

Q: What happens when I stop taking Montelex?

Stopping the medication may cause chronic asthma symptoms to return or worsen. Furthermore, in cases where patients discontinued use due to neuropsychiatric symptoms, those symptoms sometimes resolved but have also been reported to persist after the medicine was stopped.

Q: Is Montelex a Schedule V controlled substance?

No, montelukast sodium, the active ingredient in Montelex, is not classified as a controlled substance. This means it is not included in the DEA schedule classification, which is used to categorize drugs with potential for abuse or dependence.

Q: Can Montelex cause insomnia or sleepiness?

Official regulatory documentation indicates that insomnia, or difficulty sleeping, is a reported side effect of Montelex. It is classified as an uncommon reaction, potentially affecting up to 1 in 100 people. Other sleep-related issues, such as nightmares and sleepwalking, have also been noted.

Q: How is Montelex usually packaged?

Official regulatory documents describe Montelex as being supplied in multiple forms: film-coated tablets, chewable tablets, and oral granules. These are typically available in packaging like sealed bottles or blister packs, depending on the dosage and form prescribed.

Q: Why do I need to take Montelex every day?

Montelex is categorized as a controller medicine, meaning it is designed for long-term management of a chronic condition. It works by continuously blocking certain inflammatory chemicals in the body. Taking the medicine every day, as prescribed, is necessary to maintain consistent levels and achieve long-term control of asthma and allergic rhinitis symptoms.

Q: What should I do if I accidentally take two doses of Montelex?

Symptoms reported in cases of overdose include common effects like headache and abdominal pain, as well as somnolence (drowsiness) and vomiting. If someone has taken more than the amount prescribed, official guidance states that contact with a doctor or emergency services for advice is appropriate.

Q: Is it possible to become dependent on Montelex?

The active ingredient, montelukast, is not classified as a controlled substance and does not have a recognized potential for abuse or dependence. It is important to note, however, that because it is a controller medicine, stopping it may cause the underlying chronic asthma or allergic rhinitis symptoms to return.

Q: Can Montelex be crushed or split?

The official administration guidelines are specific about how different forms must be handled. Film-coated tablets should be swallowed whole and must not be chewed. Chewable tablets are designed to be chewed. Oral granules are administered directly or mixed with soft foods, but they are not intended to be crushed.

Q: What is the difference between the immediate-release and extended-release versions of Montelex?

Official regulatory information describes the available dosage forms as standard film-coated tablets, chewable tablets, and granules, which are taken once daily. The term extended-release (ER) refers to formulations specifically designed to release the medication in a controlled manner over a long period. All forms are intended for once-daily dosing.

Q: Why is Montelex not recommended for people with liver disease?

Official prescribing information states that Montelex is removed from the body primarily through bile. Because of this, caution is noted for patients with impaired hepatic (liver) function. For patients with severe liver impairment, the official safety status of the drug has not been established.

How should Montelex be stored and disposed of?

How to Store and Dispose of Montelex (Montelukast Sodium)

The storage and disposal of Montelex must strictly follow the requirements specified in the official regulatory labeling.


Official Storage Requirements

Montelex tablets and chewable tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C. The medication requires specific protection from both light and moisture and must be kept in its original container until use.

Regulatory documentation includes the mandatory instruction to keep this medicine out of the sight and reach of children to prevent accidental ingestion.


Handling and Disposal

If the oral granules are mixed with food, the entire dose must be administered immediately and not stored for later use. For disposal, any unused or expired Montelex must be handled in accordance with local requirements for pharmaceutical waste, as instructed in the official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Montelex found in:

A-Z Index: